Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multiple-ascending dose study of RG-012 for the trearmet of Alport syndrome

Trial Profile

A multiple-ascending dose study of RG-012 for the trearmet of Alport syndrome

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2018

At a glance

  • Drugs Lademirsen (Primary)
  • Indications Hereditary nephritis
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Nov 2018 Status changed from active, no longer recruiting to completed, according to a Regulus Therapeutics media release.
    • 12 May 2017 Accordign to a Regulus (10 Q SEC filings http://files.shareholder.com/downloads/AMDA-14LKIJ/4455726230x0xS1628280-17-4992/1505512/filing.pdf) media release, this study was initiated in the 2016.
    • 12 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top